NBTX logo

NBTX Nanobiotix S.A.

NASDAQ Global Select · Biotechnology · Healthcare

$26.50
-0.81 (-2.98%)

Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esoph…

Market Cap: $1.35Bwww.nanobiotix.com

Price

No data yet.

Social Signal Score

50
5d
—
30d
—
60d
50
3 mentions
—
90d
50
5 mentions
—
news: 5

Analyst Ratings

4 analysts
Buyconsensus
Strong Buy 0Buy 3Hold 1Sell 0Strong Sell 0
Avg price target$46+73.6%
Low $46Median $46High $46
Current Consensus

Revenue

$5.55M+716.14%
$-16.48M$-14.3K$16.45M$32.91M
Jun 2011Jun 2026

Analyst Estimates

FY2025
$-0.17
$-1.13–$0.79
3 analysts
FY2026
$-0.53
$-0.78–$-0.28
2 analysts
FY2027
$-0.19
$-0.92–$0.54
2 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Laurent Levy
Sector
Healthcare
Industry
Biotechnology
Employees
97
Beta
0.57
Country
FR
Piotroski score
2 / 9 (Weak)
Altman Z-score
4.10
www.nanobiotix.com